Objective: We investigated the effects of 2-year folic acid and vitamin B 12 supplementation on cognitive performance in elderly people with elevated homocysteine (Hcy) levels.
With the aging of populations, the prevalence of dementia is growing dramatically. 1 A possible modifiable risk factor of dementia is an elevated plasma homocysteine (Hcy) level. Hcy may be toxic for neurons and vascular endothelial cells, 2 and cross-sectional and prospective studies have shown associations between elevated Hcy levels and cognitive decline and dementia. 2, 3 Hcy levels can be lowered by supplementation with folic acid and vitamin B 12 . 4 Serum folate and vitamin B 12 are involved in the Hcy pathway, acting on the conversion of Hcy into methionine. Deficiencies of these vitamins may result in elevated Hcy levels, impaired DNA synthesis and methylation, and accumulation of abnormal fatty acids in membranes of neural tissue. 2, 5 This may negatively influence cognitive performance. Although observational studies have shown associations between poor vitamin B 12 and folate status and cognitive performance, 2,6 evidence from randomized controlled trials (RCTs) is limited and less convincing. 3 A meta-analysis of 13 trials in healthy elderly people did not reveal beneficial effects of supplementation with vitamin B 12 , folic acid, vitamin B 6 , or a combination of these vitamins. 3 However, studies were heterogeneous in the dosage used and study population, which makes comparisons difficult. Furthermore, only 4 trials had a study period of 1 year or longer. Therefore, we investigated the effects of 2-year folic acid and vitamin B 12 supplementation on cognitive performance in elderly people with elevated Hcy levels through a double-blind, randomized, placebo-controlled trial.
METHODS Study design and participants. The study was conducted among Dutch elderly men and women who participated in the B-PROOF (B-Vitamins for the Prevention of Osteoporotic Fractures) study. 7 The primary goal of the B-PROOF study was to assess the efficacy of oral supplementation with 400 mg folic acid and 500 mg vitamin B 12 in the prevention of fractures, with cognitive performance as secondary outcome. The study was conducted in 3 research centers in the Netherlands: VU University Medical Center (Amsterdam), Erasmus Medical Center (Rotterdam), and Wageningen University (WU, Wageningen).
The primary outcome of the current study was the difference between treatment groups in performance on episodic memory after 2 years of supplementation (Class I evidence). We hypothesized that supplementation with folic acid and vitamin B 12 would delay decline in episodic memory by, among others, lowering plasma Hcy levels. Secondary outcomes were differences in performance at follow-up on attention and working memory, information processing speed, executive function, and single test scores (Class I evidence).
Participant selection and attrition have been extensively described elsewhere. 7 In short, most participants were recruited via registries of municipalities in surroundings of the research centers. The study was conducted between October 2008 and March 2013. Inclusion criteria were age 65 years or older, having an elevated plasma Hcy level (12-50 mmol/L), being competent to make own decisions, and having a compliant tablet intake ($85%) in the run-in period. Exclusion criteria were cancer diagnosis within the last 5 years except for basal cell carcinoma and squamous cell carcinoma, bedridden, serum creatinine level .150 mmol/L, current or recent (,4 months) use of intramuscular injections of vitamin B 12 or folic acid supplementations (.300 mmol), and participation in other intervention studies.
Standard protocol approvals, registrations, and patient consents. WU Medical Ethical Committee approved the study and Medical Ethics Committees of Erasmus Medical Center and VU University Medical Center gave approval for local feasibility. All participants gave their written informed consent. This trial is registered at clinicaltrials.gov as NCT00696514 and at Netherlands Trial Register as NTR1333.
Randomization and masking. Participants were randomly allocated (1:1 ratio) to receive either a daily tablet with 400 mg folic acid and 500 mg vitamin B 12 , or a placebo for 2 years. Both tablets contained 15 mg (600 IU) of vitamin D 3 to ensure normal vitamin D status. Randomization was done by an independent person by means of computer-generated randomization numbers in stratified permuted blocks of size 4, stratified by study center, sex, age (65-79 years, $80 years), and Hcy levels (12-17 mmol, $18 mmol). Participants and employees of the study were blinded until data analyses were finished. Every 6 months, participants received new tablets and participants were requested to return any remaining tablets in order to measure compliance.
Descriptive characteristics. Standing height was measured
with a stadiometer to the nearest 0.1 cm. Weight was measured to the nearest 0.5 kg with a calibrated scale (Seca, Deventer, the Netherlands). Information about education level, marital status, living situation, smoking habits, alcohol intake, and medical history was obtained by questionnaires.
Depressive symptoms were measured with the short Geriatric Depression Scale-15, in which a score $5 indicates being at risk for depression. 8 Physical activity was measured with the Longitudinal Aging Study Amsterdam Physical Activity Questionnaire 9 ; frequency and duration of activities during the past 2 weeks were assessed to calculate physical activity in kcal/d.
Cognitive tests. Cognitive performance was assessed at baseline
and at the end of the intervention period by well-trained research assistants following a standard protocol. We used the Mini-Mental State Examination (MMSE) 10 and an extensive, sensitive, and validated neuropsychological test battery to assess the cognitive domains episodic memory, attention and working memory, information processing speed, and executive function. The battery consisted of the Rey Auditory Verbal Learning Test (RAVLT), 11 Digit Span forward and backward, 12 Trail Making Test (TMT) parts A and B, 13 Stroop Color-Word Test, 14 Symbol Digit Modalities Test, 15 and Letter Fluency (3 letters) (for a detailed description, see appendix e-1 on the Neurology ® Web site at Neurology.org). 16 The MMSE and RAVLT were performed in all 3 research centers; other tests were assessed in only the WU participants. For RAVLT, TMT, and Verbal Fluency test, validated parallel versions were used for baseline and the 2-year measurement to minimize learning effects.
RAVLT-Decay was calculated as the number of words recalled after approximately 15 minutes following the fifth session of the RAVLT, minus the number of words recalled at the fifth session of the RAVLT. To control for effect of motor speed on performance, we calculated interference measures for TMT (TMT B/TMT A) and Stroop part 3 (time needed for Stroop part 3 2 [mean time needed for Stroop parts 1 and 2]). Scores on the 3 letters of the Verbal Fluency test were summed.
To compare results of the individual cognitive tests and to limit the number of dependent variables, crude test scores were clustered into compound scores for the 4 neuropsychological domains. Data of baseline measurements were used as norm data to create individual z scores for baseline and 2-year follow-up data (z score 5 [score test 2 mean baseline]/SD baseline).
Blood markers. Before and immediately after the intervention period, blood samples through venipunction were collected in a fasted state or after a restricted breakfast to obtain whole blood, plasma, serum, and buffy coats. 7 Plasma Hcy, serum creatinine, vitamin B 12 , folate, holotranscobalamin (holoTC), and methylmalonic acid were determined. DNA was isolated to determine the genotype for methylenetetrahydrofolate reductase (MTHFR 677T) and APOE (rs 429358). Detailed methodology can be found in appendix e-1.
Statistics. Analyses were performed before unblinding of the treatment code. Intention-to-treat analyses included all participants who completed reliable baseline measurements and at least one follow-up measurement. Per-protocol analyses included those participants who were compliant to the study protocol ($80%). Data are reported as n (%), means (SD), or as median (interquartile range [IQR]) for nonnormally distributed data. Baseline characteristics were compared between treatment groups using x 2 , independent-samples t, or Mann-Whitney nonparametric tests. In addition, differences in age, sex, Hcy, and MMSE score between dropouts and participants who completed the study were tested. Differences between treatment groups over time were analyzed using analyses of covariance, in which the outcome measures at 2 years acted as dependent factor, baseline data as covariate, and treatment as fixed between-subject factor. In the fully adjusted model, age, sex, and study center were added as covariates. Because test scores on the MMSE violated normality assumptions of analyses of covariance, change over time was calculated and analyzed for treatment effects with an independentsamples t test.
For all 4 cognitive domains, predefined interaction terms of treatment with sex, baseline age (,80, $80 years), plasma Hcy (,14.4, $14.4 mmol/L), and APOE genotype (APOE e4 or not) were tested. A p , 0.10 for interaction was considered as justification for stratified subgroup analyses. Exploratory post hoc analyses were done for MTHFR genotype, and for baseline levels of vitamin B 12 , folate, methylmalonic acid, and holoTC.
A 2-sided p value of ,0.05 was considered statistically significant. All statistical analyses were performed using SPSS Statistics version 20 (IBM Corp., Armonk, NY).
RESULTS Participants. The figure shows the CONSORT (Consolidated Standards of Reporting Trials) participant flow through the study for the total study population. In the placebo group, 200 participants (14%) discontinued use of tablets, whereas this number was 222 in the B-vitamin group (15%, not significant). Dropouts were older (77.1 years, p , 0.01), had higher median Hcy concentrations (15.2 mmol/L, p , 0.01), had lower MMSE scores (median 27, p , 0.01), and were more likely to be women (16% vs 13% men, p 5 0.01) compared with persons who completed the study. Average compliance to treatment was 90%, and 84% of all participants had an overall compliance $80%. Compliance was equal for both treatment groups.
Mean age of the total population was 74.1 (SD 6.5) years, 50% were men, and mean MMSE score was 28 (IQR 27-29, range 14-30) (table 1). Baseline characteristics were equal for both treatment groups, except for serum holoTC (p 5 0.03, data not shown).
In the WU subpopulation with extensive cognitive tests (n 5 856), baseline characteristics were all similar for both treatment groups. In this subgroup, mean age was 72.6 (SD 5.8) years and 58% were men (table 1) .
Plasma Hcy levels decreased more in the B-vitamin group compared with placebo (p , 0.01) (total population). In the B-vitamin group, levels decreased from a median of 13.9 (IQR 12.9-16.2) to 9.3 (IQR 8.2-11.2) mmol/L (mean change of 25.0, 95% confidence interval [CI] 25.3 to 24.7), vs 14.4 (IQR 12.9-16.4) to 13.3 (IQR 11.5-16.0) mmol/L (mean change of 21.3, 95% CI 21.6 to 20.9) in the placebo group. As expected, the number of participants who had Hcy concentrations ,12 mmol/L differed between groups (n 5 266 in the placebo and n 5 971 in the B-vitamin group).
Cognitive performance. Mean baseline cognitive test scores did not differ between treatment groups (table e-1). In the intention-to-treat analyses (table 2), both treatment groups improved performance on episodic memory (total population) and executive functioning (subpopulation) after 2 years, but no effect of B-vitamin treatment was observed. Episodic memory improved with 0.08 (95% CI 0.05-0.12) in the placebo group and with 0.11 (95% CI 0.07-0.14) in the B-vitamin group (p 5 0.42). Performance by the subpopulation on attention and working memory, and information processing speed declined over time, but there was no treatment effect. Table 3 shows the performance on single cognitive tests at baseline and after 2 years. Performance on the MMSE, measured in the total population, decreased slightly less in the B-vitamin group (20.1, 95% CI 20.2 to 0.00) compared with the placebo group (20.3, 95% CI 20.4 to 20.2, p value for difference between groups 5 0.05). None of the other single cognitive tests at 2 years was significantly different between the treatment groups. The per-protocol analyses revealed slightly larger differences between groups, but no significant effects were observed (n 5 2,284 for episodic memory and n z 688 for the other domains) (data not shown).
Subgroup analyses. Predefined variables that were tested for interaction effects with treatment only showed a significant interaction effect for information processing speed and age. Stratified analyses in participants younger than 80 years (n 5 686) and 80 years and older (n 5 45), however, did not show any treatment effect (see tables e-2 and e-3). Results of explorative post hoc subgroup analyses did not reveal beneficial effects of vitamin B treatment, except that participants with a low holoTC concentration in the B-vitamin group improved more (0.13, 95% CI 0.08-0.18) on their episodic memory performance than the placebo group (0.08, 95% CI 0.03-0.13, p 5 0.04) (table e-3).
DISCUSSION This large randomized, placebocontrolled trial did not reveal beneficial effects of 2-year supplementation with vitamin B 12 and folic acid on the cognitive domains of episodic memory, attention and working memory, information processing speed, and executive function in elderly people with elevated Hcy levels. However, decline of global cognitive performance was slightly lower in the B-vitamin group, but the effect would have disappeared when correcting for multiple testing.
Although cross-sectional studies have often demonstrated positive associations between folate or vitamin B 12 status and cognitive performance, results from RCTs do not convincingly support this. 2 We add evidence to this with our study, which is one of the largest intervention studies up to now that investigated the effects of long-term vitamin B supplementation on global cognitive function, episodic memory, attention and working memory, information processing speed, and executive functioning in hyperhomocysteinemic elderly people. Only a few studies have shown beneficial effects of combined supplementation of folic acid and vitamin B 12 on cognitive performance: in elderly people with elevated psychological distress on overall cognitive functioning, immediate and delayed recall, 17 and in elderly people with mild cognitive impairment (MCI). 18 Like our study, most other studies that were performed in elderly people without dementia with a study duration of at least 1 year did not show significant effects of vitamin B supplementation. [19] [20] [21] One Score <25, n (%) 21 (5) 24 (6) 177 (6) GDS score, median (IQR)
Score ‡5, n (%) 21 (5) a Data available for n 5 766 in the cognitive subsample and n 5 2,570 in the total population. b Data available for n 5 816 in the cognitive subsample and n 5 2,721 in the total population. study even showed that 2-year supplementation with 500 mg vitamin B 12 and 1,000 mg folic acid resulted in worse information processing speed and overall cognitive function compared with the placebo group. 22 Supplementation with only folic acid showed mixed results; it slightly improved memory, 23, 24 information processing speed, 24 and attention, 25 but there are also studies that did not observe beneficial effects of folic acid supplementation. 26, 27 Evidence for a beneficial effect of supplementation with solely vitamin B 12 is not present. 6 We showed a small beneficial effect of vitamin B supplementation on global cognitive performance, as measured with the MMSE. In a different study of patients with MCI, and only in participants with elevated Hcy levels, a beneficial effect of moderate doses of vitamin B 12 and folic acid supplementation on the MMSE was observed (placebo group decreased with 1.2 point, B-vitamin group with 0.3 point). 18 Although the MMSE is a widely used and validated cognitive screening tool, it has limitations because of ceiling effects, and its sensitivity to detect subtle changes has been questioned, 28 especially in welleducated populations like ours. Our significant finding was therefore somewhat unexpected and may be attributable to the large study population. The difference between treatment groups in our study was only 0.2 on a maximum score of 30 and this difference is far from clinical relevance. Furthermore, based on the number of statistical tests we performed, it should be considered that our finding might be a chance finding. Adjustments for multiple testing would have resulted in nonsignificant results.
Because effects of supplementation may be more pronounced in people with higher baseline Hcy levels 18, 24 and low folate and vitamin B 12 status, 19 we analyzed predefined interaction terms. These analyses did not reveal significant results for sex, age, plasma Hcy, and APOE e4 genotype. Post hoc analyses, however, showed that participants with low holoTC levels, the active form of vitamin B 12 , had more benefits of the vitamin B supplementation on the domain of information processing speed.
In addition to our large sample size as strength of our study, is the use of validated neuropsychological tests, which enabled us to study the effects of B vitamins on a broad spectrum of cognitive functions that decline with aging. 29 By combining tests measuring the same cognitive concept, we were able to create sensitive and reliable domain compound scores and to decrease the risk of chance findings or ceiling performances. Furthermore, compliance to treatment was high, as was also reflected by decreased plasma Hcy levels in the B-vitamin group compared with a much smaller decrease in the placebo group. In addition, the duration of 2 years is adequate to induce a change in cognitive performance; according to the International Academy on Nutrition and Aging task force, a minimum of 18 months would be required. 30 Nevertheless, even though our study population was hypothesized to be at higher risk of cognitive decline because of elevated Hcy levels and therefore would be expected to be even more sensitive for changes, it is possible that the decreased plasma Hcy levels may not have revealed their possible beneficial effects yet at time of measurements. A limitation of the study design was the lack of intermediate measurements; therefore, analyses in participants without follow-up measurements were not possible. Another relevant point is that both treatment groups received vitamin D 3 . High serum 25-OH vitamin D concentrations have been associated with better cognitive performance, and lower risk of dementia. 31 RCTs investigating the effects of vitamin D 3 supplementation in elderly people, however, are scarce. Although vitamin D supplementation is recommended for elderly people in the Netherlands, still 44% of the total population was vitamin D deficient at baseline (,50 nmol/L). 32 It is possible that vitamin D supplementation diluted potential effects of vitamin B 12 and folic acid on cognitive performance, although these nutrients may have different mechanisms that account for a possible effect.
Recently, concerns have been put forward on folic acid supplementation and increased cancer risk. Post hoc analyses of adverse events in the B-PROOF population showed that participants in the B-vitamin group reported cancer more often than those in the placebo group. 33 Nevertheless, a recent meta-analysis did not observe a significant negative effect based on 13 studies. 34 Our dose of folic acid was well below the upper tolerable limit that is used in the Netherlands (1 mg/d). 35 Although our finding could be attributed to chance, we should interpret it with care and it makes daily supplementation with folic acid in the given dose questionable.
Based on the current results and results from previous RCTs, we conclude that supplementation with folic acid and vitamin B 12 did not beneficially affect cognitive performance on 4 cognitive domains in healthy elderly people with elevated Hcy levels. We cannot extrapolate this to persons who already have cognitive problems. Furthermore, cross-sectional and prospective MRI studies, 36, 37 as well as one RCT in patients with MCI, 38 observed beneficial effects of these vitamins on brain atrophy. To unravel the effects of B vitamins, a closer look into early brain pathologies would be useful to uncover subtle effects that are difficult to detect with paper and pencil tests. Within the B-PROOF study, we have anticipated on these innovative developments, and results regarding MRI are awaited.
